(+)-(S)-N-benzoyl-3-methylpiperidine | 109152-48-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (+)-(S)-N-benzoyl-3-methylpiperidine
• 英文别名: (+)-N-benzoyl-3-methylpiperidine；(S)-N-benzoyl-3-methylpiperidine；(S)-(+)-N-Benzoyl-3-methylpiperidine；[(3S)-3-methylpiperidin-1-yl]-phenylmethanone
• CAS: 109152-48-9
• 化学式: C₁₃H₁₇NO
• mdl: MFCD01212018
• 分子量: 203.284
• InChiKey: KXEVGKCOPOYOFG-NSHDSACASA-N

物化性质

• 熔点：
  72 °C
• 沸点：
  326.8±11.0 °C(Predicted)
• 密度：
  1.045±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (+)-(S)-N-benzoyl-3-methylpiperidine 在 溴 、 三溴化磷 作用下， 以39%的产率得到(-)-(S)-2-methyl-1,5-dibromopentane
  参考文献：
  名称：

  PCP receptor and dopamine uptake sites are discriminated by chiral TCP and BTCP derivatives of opposite configuration

  摘要：

  3-Methylpiperidine derivatives of 1-[1-(2-thienyl)cyclohexyl]piperidine (TCP) and 1-[1-(2-benzo[b]thiophenyl)cyclohexyl]piperidine (BTCP) were obtained in their racemic and homochiral forms. They have been tested for their affinity for the PCP receptor labeled with [H-3]TCP and for the dopamine transporter labeled with [H-3]BTCP. The homochiral TCP derivative (+)-R displayed a very high affinity (5.2 nM) and selectivity for the PCP receptor. In contrast, the homochiral BTCP derivative (-)-S, therefore of opposite configuration, displayed a very high affinity (3.5 nM) and selectivity for the dopamine transporter.

  DOI：

  10.1016/0223-5234(96)88257-2
• 作为产物：
  描述：

  苯甲酰氯 以 sodium hydroxide 为溶剂， 以98%的产率得到(+)-(S)-N-benzoyl-3-methylpiperidine
  参考文献：
  名称：

  5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines

  摘要：

  该发明涉及以下结构的二氢嘧啶化合物，这些化合物是人类α1A受体的选择性拮抗剂。该发明还涉及利用这些化合物降低眼压、抑制胆固醇合成、放松下尿路组织、治疗良性前列腺增生、阳痿、心律失常以及治疗任何需要对α1A受体进行拮抗的疾病。该发明进一步提供了一种包含上述定义化合物的治疗有效量和药用可接受载体的药物组合物。

  公开号：

  US06245773B1

文献信息

• Kinetic resolution of amines with enantiopure 3-N,N-diacylaminoquinazolin-4(3H)-ones
  作者：Al-Sehemi, Abdullah G.、Atkinson, Robert S.、Fawcett, John

  DOI：10.1039/b105917n

  日期：2002.1.7

  The title compounds (DAQs) are chiral when the two N-acyl groups are different because of the absence of rotation around the N–N bond (a chiral axis). Enantiopure DAQs have been obtained by incorporation of a chiral centre in enantiopure form either into the substituent at the Q2-position or into one of the N-acyl groups, or into both, followed by separation of diastereoisomers. This separation is unnecessary in one case because conversion of the N-monoacylaminoquinazolinone (MAQ) into the DAQ is completely diastereoselective. Neither is separation of diastereoisomers necessary with 3-[N,N-di-(S)-2-acetoxypropanoylamino]-2-diphenylmethylquinazolin-4(3H)-one 37a: this DAQ 37a has its N–N bond rendered a chiral axis by the bias in its imide moiety wholly in favour of one exo/endo conformation.The high chemoselectivity exhibited by N,N-diacetyl- or N,N-dibenzoylaminoquinazolinones in reaction with the less hindered of two secondary amines (pyrrolidine in the presence of 1 eq. of piperidine) has a stereoselective counterpart: reaction of the above enantiopure DAQs enantioselectively with racemic amines leading to kinetic resolution. Using 1 eq. of DAQ and 2 eq. of amine, both the derivatised and unreacted amine enantiomers are recovered with high enantiomeric excess (ee) (better than 90% ee in some cases). Some of the higher ees are found in the recovered amides where non-chemoselective attack on both N-acyl groups of the DAQ has occurred: from the opposite configurations of the amine component in the two amides and from the low enantiopurity of the recovered unreacted amine, reaction of each of the N-acyl groups with complementary enantiomers of the amine is occurring (parallel kinetic resolution).Although higher ees are, in general, obtained using secondary amines, high ees are obtained in some cases using 1-phenylethylamine and, in particular, amino acid esters (valine and alanine).The sense of enantioselectivity in the reactions of these DAQs with amines is controlled by the configuration of the N–N axis: replacing the Q group in an N-(S)-2-acetoxypropanoyl-N-acetyl-bearing DAQ by phthalimide, thus eliminating the N–N chiral axis, drastically reduces the level of kinetic resolution.

  标题化合物(DAQs)在两个N-酰基团不同时是手性的，因为N-N键（一个手性轴）缺乏旋转。通过将手性中心以手性形式引入Q2-位点的取代基或其中一个N-酰基团，或两者中，随后分离diastereoisomers，得到了纯对映体的DAQs。在一个情况下，这种分离是不必要的，因为将N-单酰胺基喹唑啉酮(MAQ)转化为DAQ是完全立体选择性的。对于3-[N,N-di-(S)-2-乙酰氧基丙酰胺基]-2-二苯甲基喹唑啉-4(3H)-酮37a，也不需要分离diastereoisomers：这个DAQ 37a通过其亚胺部分的偏向完全倾向于一个exo/endo构象，使其N-N键成为一个手性轴。N,N-二乙酰基或N,N-二苯甲酰氨基喹唑啉酮在与两个次级胺中较少受到阻碍的胺（在存在1 eq.的哌啶的情况下使用吡咯烷）反应时表现出高度的化学选择性，这在立体选择性上有对应：上述纯对映体的DAQs与外消旋胺反应，导致动力学拆分。使用1 eq.的DAQ和2 eq.的胺，衍生化的和未反应的胺对映体都以高对映体过量（ee）回收（在一些情况下优于90% ee）。在一些回收的酰胺中发现较高的ee，其中非化学选择性地攻击DAQ的两个N-酰基团：从两个酰胺中胺组分的相反构型和回收的未反应胺的低对映纯度，每个N-酰基团与胺的互补对映体反应（并行动态拆分）。尽管通常使用次级胺得到较高的ee，但在某些情况下使用1-苯乙胺，特别是氨基酸酯（缬氨酸和丙氨酸）得到高ee。这些DAQs与胺反应的对映选择性的方向受N-N轴配置的控制：在带有N-(S)-2-乙酰氧基丙酰基-N-乙酰基的DAQ中，通过用邻苯二甲酰亚胺替换Q组，从而消除N-N手性轴，显著降低了动力学拆分的水平。
• N-Tosyl-(S)-Prolyl Chloride in Kinetic Resolution of Racemic Heterocyclic Amines
  作者：D. A. Gruzdev、S. A. Vakarov、G. L. Levit、V. P. Krasnov

  DOI：10.1007/s10593-014-1432-4

  日期：2014.3

  The kinetic resolution of racemic heterocyclic amines via acylation with N-tosyl-(S)-prolyl chloride was systematically investigated. It was established that racemic mixtures of aromatic amines could be resolved with high efficiency, while the acylation of 2- and 3-methylpiperidines occurred with low diastereoselectivity. A method for the preparation of enantiomerically pure (3R)-7,8-difluoro-3-methyl-3

  系统研究了外消旋杂环胺经N-甲苯磺酰基-（S）-脯氨酰氯酰化的动力学拆分。已经确定，芳族胺的外消旋混合物可以高效分离，而2-和3-甲基哌啶的酰化则以低的非对映选择性发生。开发了制备对映体纯的（3 R）-7,8-二氟-3-甲基-3,4-二氢-2 H- [1,4]苯并恶嗪的方法。
• Acylative kinetic resolution of racemic methyl-substituted cyclic alkylamines with 2,5-dioxopyrrolidin-1-yl (<i>R</i>)-2-phenoxypropanoate
  作者：Dmitry A. Gruzdev、Sergey A. Vakarov、Marina A. Korolyova、Ekaterina V. Bartashevich、Andrey A. Tumashov、Evgeny N. Chulakov、Marina A. Ezhikova、Mikhail I. Kodess、Galina L. Levit、Victor P. Krasnov

  DOI：10.1039/d1ob02099d

  日期：——

  methyl-substituted cyclic alkylamines with active esters of 2-phenoxypropanoic acid was studied in detail. The ester of (R)-2-phenoxypropanoic acid and N-hydroxysuccinimide was found to be the most selective agent. The highest stereoselectivity was observed in the kinetic resolution of racemic 2-methylpiperidine in toluene at −40 °C (selectivity factor s = 73) with the predominant formation of (R,R)-amide

  详细研究了一些外消旋甲基取代的环状烷基胺与2-苯氧基丙酸的活性酯的非对映选择性酰化反应。( R )-2-苯氧基丙酸和N-羟基琥珀酰亚胺的酯被发现是最具选择性的试剂。在 -40 °C 下，在甲苯中的外消旋 2-甲基哌啶的动力学拆分中观察到最高的立体选择性（选择性因子s = 73），主要形成 ( R , R )-酰胺 (93.7% de）。为了解释观察到的立体选择性，对标题酰化剂与 2-甲基哌啶和 2-甲基吡咯烷反应中的过渡态进行了 DFT 建模。计算值与实验数据吻合良好。已经证明酰化通过协同机制进行，其中胺的添加与羟基琥珀酰亚胺片段的消除同时发生。与 ( R , S )-酰胺的形成相比，( R , R )-酰胺形成的高立体选择性很大程度上是由过渡态中较低的空间位阻确保的。
• [EN] DIHYDROPYRIMIDINES AND USES THEREOF<br/>[FR] DIHYDROPYRIMIDINES ET LEURS UTILISATIONS
  申请人：SYNAPTIC PHARMACEUTICAL CORPORATION

  公开号：WO1996014846A1

  公开（公告）日：1996-05-23

  (EN) This invention is directed to dihydropyrimidine compounds which are selective antagonists for human $g(a)1C receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotence, cardiac arrhythmia and for the treatment of any disease where the antagonism of the $g(a)1C receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.(FR) Cette invention se rapporte à des composés dihydropyrimidine qui sont des antagonistes sélectifs pour les récepteurs $g(a)1C humains, ainsi qu'aux utilisations de ces composés dans la réduction de la pression intraoculaire, l'inhibition de la synthèse du cholestérol, le relâchement des tissus inférieurs des voies urinaires, le traitement de l'hyperplasie prostatique bénigne, l'impuissance, l'arythmie cardiaque et le traitement de toutes maladies pour lesquelles l'antagonisme du récepteur $g(a)1C peut être utile. L'invention se rapporte encore à une composition pharmaceutique comprenant une quantité thérapeutiquement efficace des composés définis ci-dessus et à un excipient pharmaceutiquement acceptable.

  这项发明涉及选择性拮抗人类$g(a)1C受体的二氢嘧啶化合物。该发明还涉及使用这些化合物降低眼内压、抑制胆固醇合成、放松下尿路组织、治疗良性前列腺增生、阳痿、心律失常以及治疗任何需要拮抗$g(a)1C受体的疾病。该发明还提供了一种制药组合物，包括上述定义的化合物的治疗有效量和药用载体。
• [EN] DIDHYDROPYRIMIDINES AND USES THEREOF<br/>[FR] DIHYDROPYRIMIDINES ET LEURS EMPLOIS
  申请人：SYNAPTIC PHARMACEUTICAL CORPORATION

  公开号：WO1997042956A1

  公开（公告）日：1997-11-20

  (EN) This invention is directed to dihydropyrimidine compounds which are selective antagonists for human $g(a)1A receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia and for the treatment of any disease where the antagonism of the $g(a)1A receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.(FR) L'invention concerne des composés de dihydropyrimidine qui sont des antagonistes sélectifs de récepteurs humains $g(a)1A. L'invention concerne également les emplois desdits composés pour abaisser la pression intraoculaire, inhiber la synthèse du cholestérol, soulager le tissu du bas appareil urinaire, ainsi que pour traiter l'hyperplasie prostatique bénigne, l'impuissance, l'arythmie cardiaque et toute autre maladie pour laquelle l'antagonisme du récepteur $g(a)1A peut être utile. L'invention décrit en outre une composition pharmaceutique contenant une dose thérapeutiquement efficace des composés susmentionnés et un excipient pharmaceutiquement admissible.

  (中) 本发明涉及二氢嘧啶化合物，其是人类$g(a)1A受体的选择性拮抗剂。本发明还涉及使用这些化合物降低眼压、抑制胆固醇合成、放松下尿路组织、治疗良性前列腺增生、阳痿、心律失常以及治疗任何可能有用的$g(a)1A受体拮抗剂的疾病。本发明还提供了一种药物组合物，包括上述定义化合物的治疗有效量和药用载体。